Lupin’s Karkaria Addresses Biosimilars Pushback
Questions Need For Separate Studies On Interchangeability
Executive Summary
Lupin's biotech president notes push-back by innovator firms against biosimilars in the US parallels that witnessed when small molecule generic competition first emerged, but remains confident that biosimilars will gain traction. The executive also sees little need for separate interchangeability studies.